Skip to content

Tongji-Ezhou Study

Tongji-Ezhou Prospectively Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03845868
Acronym
TJEZ
Enrollment
10000
Registered
2019-02-19
Start date
2013-04-16
Completion date
2025-12-31
Last updated
2019-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Diabetes, Environmental Exposure, Metabolic Syndrome, Nutritional and Metabolic Diseases, Obesity, Risk Factor, Cardiovascular

Brief summary

Tongji-Ezhou study (TJEZ) is a prospective cohort study launched at 2013 in EZhou city, Hubei province, with the goal of recruiting and assessing 10,000 individuals and then following them for at least 2 decades. In addition, blood samples would be collected every 3-5 years among 6000 of them to investigate the nutritional biomarkers and potential determinants of chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease.

Interventions

OTHERDietary and environmental exposure (Observational study)

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years

Inclusion criteria

* (i) permanent residence in Ezhou district (minimum of 9 months); (ii) written informed consent; (iii) age ≥ 20 years old at the time of enrolling in the study.

Exclusion criteria

* (i) with chemotherapy or radiotherapy for cancer and other severe diseases.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of diabetes5 yearsType 2 diabetes was diagnosed when FPG ≥ 7.0 mmol/L and/or OGTT2h ≥ 11.1 mmol/L, or using diabetic medication (self-report).
Incidence of metabolic syndrome5 yearsMetabolic syndrome is defined as using the updated National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans. These criteria require three or more of the following components: (1) central obesity (waist circumference of ≥90 cm for men or ≥80 cm for women), (2) triglycerides of ≥1.7 mmol/L, (3) HDL-C of \<1.03 mmol/L for men or \<1.30 mmol/L for women, (4) blood pressure of ≥130/85 mmHg or on medication for hypertension, and (5) fasting glucose of ≥5.6 mmol/L.
Diabetic complicationsmean follow up of 10 yearsDevelopment of diabetic complications
Incidence of cardiovascular diseasesmean follow up of 10 yearsCardiovascular death, stroke, myocardial infarction, heart failure

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026